Successful therapy with rituximab of refractory acute humoral renal transplant rejection: A case report

Celik A., Saglarn F., Cavdar C., Sifil A., ATİLA K., SARIOĞLU S., ...More

TRANSPLANTATION PROCEEDINGS, vol.40, no.1, pp.302-304, 2008 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 40 Issue: 1
  • Publication Date: 2008
  • Doi Number: 10.1016/j.transproceed.2007.11.011
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.302-304
  • Dokuz Eylül University Affiliated: Yes


Acute humoral rejection (AHR) is generally less responsive to conventional anti-rejection treatment with consequent allograft losses. Therapeutic options include antilymphocyte antibody (ATG), intravenous immunglobulin (IVIG), plasmapheresis, or immunoadsorption with protein A together with intensification of immunsuppression with a tacrolimus/mycophenolate mofetil combination. This report describes a transplant recipient who responded to rituximab therapy as treatment for steroid-, ATG-, IVIG-, and plasmapheresis-resistant AHR.